Fixed Duration PVR

Clinical caseHematology2 min

A 68-year-old patient has relapsed chronic lymphocytic leukaemia after previous therapy that included a covalent BTK inhibitor. They have not previously received venetoclax, another BCL2 inhibitor, or a non-covalent BTK inhibitor.

What does the evidence from this abstract support for patients like this with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma?

Get started